H2R Tuesday, 11/05/19 05:47:31 PM Re: None Post # of 196 EPS beats by $0.34, beats on revenue Portola Pharmaceuticals (NASDAQ:PTLA): * Q3 Non-GAAP EPS of -$0.53 beats by $0.34; * GAAP EPS of -$0.68 beats by $0.20. * Revenue of $36.8M (+159.2% Y/Y) beats by $2.16M. https://seekingalpha.com/news/3514823-portola-pharmaceuticals-eps-beats-0_34-beats-revenue That continues the positive trend on Andexxa and the balance sheet looks better. Quote:- Andexxa Now Stocked in Approximately 550 U.S. Hospitals; 76% of U.S. Sales from Reorders - - Expanded Market Opportunity with Strong Initial Ondexxya Demand in Europe - - Strengthened Balance Sheet; Added Net Proceeds of $245 million in Third Quarter - A good quarter.